SAN JOSE, Calif.—Global Industry Analysts’ (GIA) U.S. & European market report—“Coenzyme Q10: A U.S. & European Market Report”—on the coenzyme Q10 (CoQ10) industry is projecting a global rise that will exceed $133.3 million by the year 2015, primarily due to the growing importance of CoQ10 in food and beverage processing industries, and emerging role of the coenzyme in heart health, cognitive health (including CoQ10’s role in delaying the onset of Parkinson’s disease) and anti-aging sectors. GRAS status and enhanced availability, as well as the growing market for non-caffeinated energy confirm CoQ10’s use in the food and beverage processing industries.
The United States’ CoQ10 market represents a major piece of the market. Heart-health benefits, doctor recommendations, low and stabilized prices, and its usefulness in controlling various diseases such as gingivitis and Parkinson's disease are driving the CoQ10 market growth in the United States. Besides being used for energy and cardiac benefits, CoQ10 is also gaining market for its usage in obesity, fertility and eye care. The product is increasingly being used in food and beverages, as well as in personal care products.
Coenzyme Q10: A U.S. & European Market Report
Europe represents another piece of the CoQ10 pie. European manufacturers and marketers, who had already capitalized on the coenzyme’s proven cardiac benefits, witnessed significant enhancements. Market players are increasingly emphasizing on the newly discovered benefits of the coenzyme, particularly in healthy vision, infertility treatments, cellular energy production and migraine relief.
Major regional and global players profiled in the report include DSM Nutritional Products, Gnosis SpA, Kyowa Hakko U.S.A. Inc., Mitsubishi Gas Chemical America Inc., ZMC-USA LLC, Hwail Pharmaceutical Co. Ltd., Kaneka Corp., PharmaEssentia Corp., Mitsubishi Gas Chemical Co., and Nisshin Seifun Group Inc.